Clinical features of LRRK2-associated Parkinson's disease

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 111, Issue 12, 2011, Pages 56-62

  Pchelina, S N ^a   Ivanova, O N ^a   Emelyanov, A K ^a   Yakimovskii, A F ^a  

^a NONE

Author keywords

L dopa; LRRK2; Parkinson's disease

Indexed keywords

LEVODOPA; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

AGED; ARTICLE; CHEMISTRY; FEMALE; GENETICS; HUMAN; MALE; MUTATION; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PEDIGREE; PROTEIN TERTIARY STRUCTURE;

AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LEVODOPA; MALE; MUTATION; PARKINSON DISEASE; PEDIGREE; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES;

EID: 84861438998     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Elbaz A. LRRK2: bridging the gap between sporadic and hereditary Parkinson's disease. Lancet Neurol 2008; 7: 7: 562-564.
2. Giasson B.I., Van Deerlin V.M. Mutations in LRRK2 as a cause of Parkinson's disease. Neurosignals 2008; 16: 1: 99-105.
3. Golub Y., Berg D., Calne D.B. et al. Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. Parkinsonism Relat Disord 2009; 15: 7: 539-541.
4. Haugarvoll K., Rademakers R., Kachergus J.M. et al. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 2008; 70: 16 Pt 2: 1456-1460.
5. Healy D.G., Falchi M., O'Sullivan S.S. et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008; 7: 7: 583-590.
6. Kay D.M., Kramer P., Higgins D. et al. Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation. Mov Disord 2005; 20: 8: 1077-1078.
7. Lesage S., Belarbi S., Troiano A. et al. Is the common LRRK2 G2019S mutation related to dyskinesias inNorth African Parkinson disease? Neurology 2008; 71: 19: 1550-1552.
8. Lasage S., Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. HumanMolecular Genetics 2009; 18: 1: 48-59.
9. Nishioka K., Kefi M., Jasinska-Myga B. et al. A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease. J Neurol Neurosurg Psychiatry 2010; 81: 4: 391-395.
10. Paisan-Ruiz C., Jain S., Evans E.W.W. et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004; 44: 595-600.
11. Paisan-Ruiz C., Lang A.E., Kawarai T. et al. LRRK2 gene in Parkinson's disease: mutation analysis and case control association study. Neurology 2005; 65: 5: 696-700.
12. Payami H., Larsen K., Bernard S., Nutt J. Increased risk of Parkinson's disease in parents and siblings of patients. Ann of Neurol 1994; 36: 659-661.
13. Pchelina S.N., Yakimovskii A.F., Ivanova O.N. et al. G2019S LRRK2 Mutation in Familial and Sporadic Parkinson's Disease in Russia. Mov Disord 2006; 21: 12: 2234-2236.
14. Pchelina S.N., Yakimovskii A.F., Emelyanov A.K. et al. Screening for LRRK2 mutations in patients with Parkinson's disease in Russia: identification of a novel LRRK2 variant. Eur J Neurol 2008; 15: 692-696.
15. Seol W. Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease. BMB Rep 2010; 43: 4: 233-244.